A strategy to circumvent immune responses to adenovirus (Ad) resulting from natural infection or repeated vector administrations involves sequential use of vectors from different Ad serotypes. To further develop an Ad-HIV recombinant AIDS vaccine approach, a replication-defective recombinant Ad from a non-subgroup C virus was required. Using a cosmid system, we generated an Ad7DE1DE3HIV MN env/rev recombinant virus and compared expression of the inserted HIV genes with a similarly constructed replicationcompetent Ad7DE3HIV MN env/rev recombinant. Ad7DE1-DE3HIV MN env/rev expressed both HIV env and rev gene products. The envelope protein was correctly processed and functional, mediating syncytia formation of Ad7DE1DE3HIV MN env/rev-infected cells and CD4 + T lymphocytes. Ad7DE1-DE3HIV MN env/rev could be amplified on 293-ORF6 cells, containing the E4 ORF6 gene, shown earlier to support production of an Ad7 vector lacking the E1a gene. The utility of this cell line is now extended to the production of replication-defective Ad7 recombinants lacking E1a, E1b, and protein IX genes. Sequential immunizations with Ad-HIV recombinants based in different Ad serotypes have been shown to effectively elicit both humoral and cellular HIVspecific immune responses. The recombinant Ad7DE1DE3-HIV MN env/rev will be useful in such AIDS vaccine strategies. Further, these studies have created new cosmid vectors that can be applied to generation of single-or double-deleted Ad7 recombinants with foreign genes inserted into the E1 and/or E3 regions.
Introduction
Among various vectored delivery systems, adenovirus (Ad) vectors possess several advantages for both gene therapy and vaccine strategies. [1] [2] [3] [4] [5] [6] They can efficiently infect both proliferating and quiescent cells from a wide variety of tissues and species. They can multiply infect a single cell 7 and are easily purified to high titers. Although Ad vectors confer long-term expression of their inserted gene products, they do not integrate into the host chromosome, which makes them suitable for applications requiring transient gene expression. As live vaccine vectors, Ad recombinants elicit humoral and cellular immune responses, both necessary for protective efficacy. In addition, as Ads replicate in the epithelium of the upper respiratory track and gut, they can induce good mucosal immune responses, essential for the prevention of mucosally and sexually transmitted infections.
Ad recombinants have been developed either as replication-competent [8] [9] [10] or as replication-defective viruses. 9, [11] [12] [13] The former may be advantageous for vaccine applications where low dose administration of the replicating vector can elicit persistent immune responses. Replication-deficient Ad recombinants, used extensively in gene therapy strategies, have attracted increasing attention as vaccine vectors, in part because of their ability to limit expression in vivo to the gene encoding the vaccine antigen. To date, all replicationdefective Ad vectors have been constructed from subgroup C viruses, most commonly serotype 5 (Ad5), and have demonstrated very efficient gene transfer in vitro and in vivo. 14, 15 Immunity to Ad may limit the utility of Ad vectors for gene therapy in particular, where prolonged, high-level expression of the transgene is required and generally achieved by repeated administration of the Ad recombinant. Natural Ad infection can induce both humoral and cellular immune responses to the Ad vector itself, thus limiting its usefulness. 16, 17 Repeated administration with the same Ad vector may be problematic because the vector induces high levels of Ad-specific antibody, which may directly impair viral attachment and penetration, precluding expression of the gene insert upon subsequent administration. 18 Cellular cytotoxic responses can also destroy Ad-transduced cells, again dramatically reducing persistent expression of the transgene.
Numerous approaches have attempted to minimize anti-vector immune responses. Administration of immunosuppressive drugs at the time of Ad vector administration, as well as transient subversion of the host immune system by blocking the function of costimulatory molecules, has temporarily allowed repeat vector administration. [20] [21] [22] [23] However, complications and potential side effects make these drugs impractical for clinical use. The newly developed second-generation Ad vectors with deletions in E2 or E4 genes in addition to E1 and E3 24 and third-generation vectors lacking all viral coding sequences 25 can lead to reduced inflammatory and cellular immune responses. However, they do not overcome humoral immune responses, and the resultant neutralizing antibodies again may impair the effectiveness of Ad vector readministration. 26 One approach to circumvent induction of anti-Ad immunity upon repeated vector administration involves the sequential use of vectors from different Ad serotypes. This approach has been applied to both gene therapy and vaccine strategies. 25, [27] [28] [29] [30] [31] [32] [33] Ad serotypes are distinguished on the basis of their resistance to neutralization by typespecific neutralizing antibodies that bind to epitopes on the virion hexon protein and the terminal knob of the fiber protein. Theoretically, the availability of 51 known serotypes among the six subgroups of human Ad provides considerable flexibility for development of vectors of different subtypes to circumvent potential problems of pre-existing host immunity in the population by sequential immunizations with different vectors. However, development of replication-defective Ad from other subgroups or species (avian, canine, primate) requires a considerable effort because of a paucity of molecular data on alternative serotypes and the necessity for serotype-matched E1 complementing cell lines, able to provide essential E1 functions in trans for virus production.
Human Ad vaccines, both type 4 (subgroup E) and type 7 (subgroup B), have been successfully used for over 25 years in military recruits to protect against outbreaks of Ad-induced acute respiratory disease. 34 The proven safety and efficacy of these vaccines makes these viruses excellent candidates for additional vaccine vectors to complement existing Ad5 (subgroup C) vectors. 35 Although replication-competent, E3 regiondeleted Ad4 and Ad7 vectors and an E1a-deleted Ad7 vector have been constructed, [36] [37] [38] there are no reports describing a vector lacking the entire E1a and E1b genes from a non-subgroup C Ad. An Ad vector with an E1b gene deletion is desirable not only as it provides more space for insertion of larger gene inserts, but also as it exhibits reduced pulmonary inflammation following infection of cotton rats and mice. 39 Further, no doubly deleted Ad7 vectors lacking both E1 and E3 region genes have yet been described.
We have pursued an AIDS vaccine approach employing replication-competent Ad-HIV or SIV recombinant priming followed by boosting with HIV or SIV envelope protein. 27, 30, [40] [41] [42] [43] [44] Our strategy provides for sequential administration of Ad recombinants of different serotypes. Recently, the utility of a replication-defective Ad5-SIV recombinant as a protective vaccine was reported. 45 In order to compare immunogenicity and protective efficacy of replication-competent and replication-defective Ad-HIV recombinants as putative vaccines, we require both an Ad5DE1DE3 vector and a similarly deleted non-subgroup C Ad vector. The former can be readily constructed from existing commercially available materials. Such reagents are not available for nonsubgroup C vectors, however. Here, we describe construction of an Ad7-HIV recombinant with deletions of E1a, E1b, and E3 genes using a cosmid system. The pIX coding sequences were also deleted, creating more space for foreign gene inserts and further diminishing any potential homologous overlapping sequences with Ad5 sequences present in 293-based packaging cell lines. HIV env and rev genes were inserted in the E3 region.
An outgrowth of generating the Ad7DE1DE3-HIVenv/ rev recombinant is the creation of a new Ad7 cosmid system consisting of individual Ad7 shuttle vectors and three recombinant Ad cosmids. These will be useful for construction of new double-recombinant Ad7 recombinants and for the easy manipulation of Ad7 DNA and further characterization of Ad7 genome. A cosmid system for manipulating multiply deleted Ad5 vectors has recently been described. 46 
Results

Construction of recombinant adenoviral cosmids
The Ad7 genome is a double-stranded DNA about 37 kb in size. Two-thirds of the genome have not been sequenced. Further, little help in identification of restriction endonuclease sites is provided by knowledge of the Ad2 or Ad5 nucleic acid sequences, since the overall homology between these viruses and Ad7 is poor. Therefore, a strategy for Ad7 recombinant construction was chosen that would allow cloning and manipulation of large DNA fragments. Cosmids can accommodate DNA inserts of 30-42 kb in size, allowing insertion of the entire Ad7 genome. A further advantage of the cosmid system is that following construction, the Ad7 recombinant DNA can be directly released from the cosmid for transfection of appropriate cell lines for Ad production ( Figure 1 ). This results in a highly efficient approach that eliminates the time-consuming steps of homologous recombination and repetitive plaque purifications necessary to insure purity of the Ad recombinant preparation. A cosmid approach was therefore selected for construction of the Ad7DE1DE3HIV MN env/rev recombinant.
As described in Materials and methods, following construction of the several recombinant plasmids illustrated in Figure 2a , three Ad7 cosmids were constructed (Figure 2b ). cAd7, containing the entire wild-type Ad7 genome, will be useful for propagating large amounts of Ad7 DNA for use in determining the viral DNA sequence and further characterizing the genome. cAd7-DE3HIV MN env/rev-N contains the Ad7 genome with the HIV env and rev genes in the deleted E3 region. This construct allows generation of a replication-competent Ad7 recombinant following transfection into mammalian cells. The cosmid contains two EcoR I sites flanking the Ad7DE3HIV MN env/rev genome, which are used to release the Ad7 genome from the cosmid for transfection. cAd7DE1DE3HIV MN env/rev allows generation of a replication-incompetent Ad7-recombinant with the HIV genes inserted into the E3-deleted region. A unique 5 0 -flanking Aat II site and a 3 0 -flanking Mlu I site can be used to release the viral genome and rescue the virus.
Generation of a replication-defective Ad7 vector X Nan et al
Generation and molecular analysis of Ad recombinant viruses
The replication-competent recombinant virus, Ad7DE3-HIV MN env/rev, was produced from the cAd7DE3HIV MN env/rev-N cosmid following release of the Ad genome by digestion with Eco R1 and transfection of 293 cells. However, the 293 cell line, containing Ad5 nucleotides 1-4344 47 encompassing the E1 region genes and pIX coding sequences, was not able to support production of the Ad7DE1DE3HIV MN env/rev recombinant in spite of the significant homology among various Ad serotypes in both the E1a 48 and E1b 49, 50 genes. We therefore attempted generation of the Ad7DE1DE3HIV MN env/rev recombinant on the 293-ORF6 cell line. 51 These cells were previously shown to be able to support production of an E1a-deleted Ad7 virus. 38 cAd7DE1DE3HIV MN env/rev was digested with Aat II and Mlu I to release the Ad genome and transfected into 293-ORF6 cells using the Ca 2 PO 4 method as described in Materials and methods. The Ad7DE1DE3HIV MN env/rev recombinant virus was readily produced on the 293-ORF6 cells.
Restriction enzyme analysis was carried out to determine the identity of the Ad recombinants. The E1-deleted Ad7 recombinant digested with Sal I should have four bands: 2.93, 4.70, 6.89, and 20 kb. In contrast, an Ad7 recombinant with an intact E1 region should have an E1-containing 6.37 kb large band instead of an E1-deleted 2.93 kb small band following digestion with Sal I. As shown in Figure 3a , the Ad7 recombinants gave DNA fragments of the predicted size by restriction analysis.
The E1 regions of the Ad7 recombinants were also analyzed using PCR. The E1-deleted and E1-containing Ad7 recombinant viruses were expected to exhibit a 535 bp and a 3966 bp band, respectively. As shown in Figure 3b , the amplified E1 regions of the individual Ad7 recombinants were correct in size. Sequencing of the E1 regions further confirmed the presence of the E1 region in the Ad7DE3HIV MN env/rev recombinant and its absence in the Ad7DE1DE3HIV MN env/rev recombinant virus (not shown).
Expression and processing of HIV Env and Rev proteins by cells infected with the Ad7 recombinant viruses
HIV-1 Rev protein binds to its target sequence on incompletely spliced RNAs and channels these RNAs into the CRM1-dependent pathway. 52, 53 This allows nuclear export of intron-containing RNAs that are normally restricted to the nucleus. Since Ad replicates in the host cell nucleus, the rev gene is required to transport HIV env mRNA into the cytoplasm. To assess the presence of the HIV rev gene products in cells infected with the Ad7 recombinants, we tested infected cell lysates by Western blot analysis ( Having verified expression of the rev gene, expression of the HIV env gene was next evaluated. Lysates of cells infected with the Ad7 recombinants were immune precipitated using an HIV gp41-specific antibody, and (Figure 6c and b, respectively) . This result indicates that HIV envelope protein produced by this Ad7 recombinant is expressed at the surface of 293-ORF6 cells and is properly processed, so that gp120 can bind CD4 receptors on the CEMX174 cells resulting in fusion and formation of multinucleated giant cells.
Application of Ad7DE1DE3HIV MN env/rev to AIDS vaccine strategy
The utility of sequential administration of replicationincompetent Ad recombinants of different serotypes to circumvent pre-existing or vector-induced immunity has been reported for gene therapy approaches. 25, 28, 29, [31] [32] [33] A similar strategy has been applied to AIDS vaccine development, using replication-competent E3-deleted , and a unique EcoR I site at the deleted E1 region. pAd7LDE1 and cAd7LDE1 were derived from pBluescript and Supercos 1, respectively. pAd7 M was generated by insertion of Ad7 middle Sal I-Sal I fragment (20 kb) at the Sal I site of pUC19 vector. pAd7RDE3 was derived from pBR328 and contains an Ad7 right Sal I fragment (68-100 mu) except for deletion of E3 gene (80-88 mu) and an unique Xba I site at the deleted E3 region (Wyeth Lederle Vaccines, Pearl River, NY, USA). (B) Recombinant cosmids cAd7, cAd7DE3HIV MN env/ rev-N, and cAd7DE1DE3HIV MN env/rev contain the wild-type Ad7 genome, the Ad7DE3HIV MN env/rev recombinant genome, and the Ad7DE1DE3-HIV MN env/rev recombinant genome in the cosmid vector, respectively. The recombinant viral genomes contain the TPL-env-TPL-rev transgene in the deleted E3 region. The viral genomes are released by the flanking unique restriction endonuclease sites described on the maps. Cosmids are not drawn to scale.
Generation of a replication-defective Ad7 vector X Nan et al Ad4-, Ad5-, and Ad7-HIV recombinants. As summarized in Table 1 , such an approach has effectively induced HIVspecific humoral and cellular immune responses in dog and chimpanzee models 27, 30, 43, 54 following sequential immunizations by intratracheal, oral, or intranasal routes of administration. Antibodies induced included both binding antibodies to HIV envelope protein detected by ELISA and Western blot, and antibodies able to neutralize T-cell-line-adapted and primary HIV isolates. Induction of cellular immunity is illustrated by T-cell proliferative responses to HIV envelope protein. As Ad5DE1DE3HIV recombinants are now also being developed as AIDS vaccine candidates, 45 it will be important to compare the immunogenicity and protective efficacy of the replication-defective and replicationcompetent Ad-HIV recombinants. Each vector type has potential advantages and disadvantages. 1 The Ad7DE1-DE3HIV MN env/rev and other HIV recombinants constructed using the cosmid system developed here, will allow this comparison to be conducted without complication of immunity to the vector itself, using sequential immunization with either double-deleted replicationdefective recombinants or single E3-deleted replicationcompetent recombinants.
New vectors for the construction of single-or doublerecombinant Ad
An outgrowth of this work on constructing the Ad7-DE1DE3HIV MN env/rev for use in AIDS vaccine studies is the creation of a new Ad7 cosmid system consisting of the left (pAd7LDE1 or cAd7LDE1) and right (pAd7RDE3) Ad7 shuttle vectors, pAd7 M containing the large Ad7 middle fragment, and three recombinant adenoviral cosmids (Figure 2a and b) . Gene expression cassettes can be inserted into the E1 or/and E3 regions by cloning into the EcoR I site created in the left shuttle vectors cAd7LDE1/pAd7LDE1 or into the Xba I site of the right shuttle vector pAd7RDE3 and then ligated together with the large middle Sal I fragment from pAd7M and the cos arm(s). In the case of the cAd7LDE1 as a left shuttle vector, only the small cos arm is required for packaging. By contrast, the large cos arm is also necessary for packaging when utilizing pAd7LDE1 as a shuttle vector. Generation of a replication-defective Ad7 vector X Nan et al Alternatively, the three Ad7 recombinant cosmids can be used to construct new cosmids in combination with the shuttle vectors. Furthermore, the recombinant Ad7 cosmids can easily be used to manipulate the Ad DNA for characterization of the Ad7 genome, restriction analysis, and cloning purposes. Such use overcomes the traditional difficulty of DNA isolation following virus purification directly from infected cells.
Discussion
Three methods have been commonly used for construction of recombinant Ad: in vitro ligation, in vitro homologous recombination, and in vivo homologous recombination. 55 The in vitro methods are useful only for Ad genomes of known sequence, however, and in vivo recombination is inefficient and can be problematic owing to parental virus contamination. Since we had only limited sequence information about the Ad7 genome, we used a cosmid system 56 to construct an Ad7DE1DE3HIV MN env/rev for use in AIDS vaccine studies. Cosmids can accommodate foreign DNA inserts ranging in size from 30 to 42 kb and allow recombinant viral DNA to be obtained easily and efficiently. With the cosmid system, the recombinant Ad genome is constructed by in vitro ligation followed by phage-mediated cosmid amplification. The resultant recombinant Ad is generated by releasing the Ad genome from the cosmid [57] [58] [59] and transfecting a permissive cell line. The replication-defective Ad7DE1DE3HIV MN env/rev recombinant generated was able to express both HIV Rev and Env proteins in human cell lines transformed with and without Ad E1 genes. The fact that the replication-defective recombinant expressed both proteins on A549 cells implies that adequate expression of the inserted HIV gene products would also occur following in vivo infection of people or animal models. That the Ad7DE1DE3HIV MN env/rev recombinant expresses functional envelope protein in infected cells was also demonstrated. The HIV envelope glycoprotein is expressed as a precursor protein, gp160, in HIVinfected CD4 + T-lymphocytes. The gp160 precursor is further cleaved by a trypsin-like host cell protease to generate the outer surface glycoprotein, gp120, and the transmembrane glycoprotein, gp41. This specific cleavage process is required for biologic activity, namely fusion of the envelope protein with cells bearing the primary CD4 receptor and coreceptors, and resultant viral entry. 60 The demonstration that cells infected with the replication-defective Ad7 recombinant formed syncytia upon incubation with CEMX174 cells confirms that HIV envelope was properly processed into gp120 and gp41, and was conformationally appropriate for cell interactions.
A continuing difficulty in the development of E1-deleted Ad vectors of non-subgroup C serotypes is the necessity for a complementing cell line able to produce the virus. The 293 cell line has been typically used for Ad5 vector production, as it was transformed with the Ad5 E1 region genes, 61 and hence provides E1 gene functions in trans. Although the Ad7DE1DE3HIV MN env/ rev recombinant can infect 293 cells, we found that the recombinant virus could not be amplified on these cells. Previously, 293-ORF6 cells, containing the E4 ORF6 gene, were shown to support the production of an Ad7 vector deleted in the E1a gene. 38 Here, we extend this work by demonstrating production of an Ad7 recombinant virus deleted of both E1 genes and pIX coding sequences on the 293-ORF6 cells. Use of a non-matched packaging cell for viral production may provide an additional safety feature in applications where replication-incompetent Reports have demonstrated that E1B gene products interact with the E4 ORF 6 gene products and form a functional complex. The nuclear export signal within the E4ORF6 protein in the complex supports virus replication and cytoplasmic accumulation of viral mRNA. 62, 63 Therefore, our inability to generate a recombinant Ad virus in 293 cells may be caused by a lack of serotypespecific E1B-E4 ORF 6 interactions.
A more generalized outcome of this work is the creation of new Ad7 vectors with deletions of the entire E1 region or of both E1 and E3 regions for application in gene therapy and vaccine approaches. The latter vector allows insertion of 7-8 kb of foreign DNA. Replicationdefective Ad vectors continue to be heavily utilized for gene therapy. Both replication-defective and replicationcompetent Ad recombinants are being exploited for vaccine approaches. It is not yet clear which type of vector will be most advantageous for vaccine development.
The availability of both replication-competent and replication-defective subgroup B Ad7 vectors should prove useful in circumventing immunity to the commonly used Ad5 vectors elicited by natural infection or previously administered Ad5 recombinants. A consequence of such immunity can be lessened expression levels of inserted foreign gene products. Thus, the vectors described here should contribute to combination gene therapy and vaccine approaches by providing a means for effective, sequential administration of transgenes via Ad recombinant vectors.
Materials and methods
Cells, media, and viruses A549 cells derived from a human lung carcinoma (ATCC CCL-185) were maintained in Kaighn's modification of Ham's F12 medium. The Ad-transformed human embryonic kidney cell line 293, 61 the 293-ORF6 cell line (293 cells containing ORF6 of the Ad5 E4 gene 51 ), and QBI-293A cells (Q-BIOgene AES0503), a more adherent subclone of the 293 cell line, were grown in Dulbecco's modified Minimal Essential Medium (DMEM) supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin, and 50 mg/ml streptomycin, at 371C in a 100% humidified atmosphere of 5% CO 2 . Wild-type Ad7 virus and recombinant Ad7DE3HIV MN env/rev virus, prepared as previously described, 36 were obtained from Wyeth Lederle Vaccines (Pearl River, NY, USA) under a Cooperative Research and Development Agreement (CRADA).
Construction of recombinant plasmids
Plasmid DNA was extracted and purified using Qiagen columns (QIAGEN). Small restriction DNA fragments were separated by gel electrophoresis and purified with 27 ELISA assays were carried out using whole HIV lysates. Mean titers and range of responses are summarized for eight dogs. Panel B: The indicated Ad-HIV recombinants were administered orally in the sequence shown at 0, 7, and 26 weeks. 54 Proliferative responses to HIV gp160 protein are recorded as stimulation indices (SI). Panel C: Chimpanzees were immunized sequentially at 12-week intervals intranasally. 30, 43 ELISA absorbance values against HIV MN gp120 are shown. Neutralizing antibody assays were carried out against T-cell-line-adapted (TCLA) HIV MN , HIV MN cultured continuously in human PBMCs, and the primary isolate BZ167. NA=not applicable; ND=not done.
Generation of a replication-defective Ad7 vector
X Nan et al Jetsorb kits (Genomed). Large virus or plasmid DNA fragments were isolated from 0.8% low melting point agarose gels (Invitrogen). Cloning of plasmid DNA fragments was performed using standard methods 56 and verified by restriction endonuclease analysis and DNA sequencing. The left Sal I fragment (1-6, 357 bp) from Ad7 was first cloned into the Sma I-Sal I (415-430 bp) deleted pUC19 vector (Invitrogen) generating pAd7L. The EcoR I-Pvu II digested, filled-in fragment (1-466 bp) from pAd7L, including the left inverted terminal repeat (ITR) and the packaging signal of Ad7, was inserted at the Sma I site of the plasmid pBluescript II KS (+) (Stratagene), yielding pAd7I. The E1a (467-2711 bp)-deleted plasmid pAd7DE1a was constructed by inserting two adenoviral fragments, Hind III-Sma I (2712-4617 bp) and Sma I-Sal I (4618-6357 bp), from pAd7L downstream of the adenoviral fragment in pAd7I. The Hind III-Sal I fragment (1211-1226 bp) at the mutiple cloning site was deleted and unique EcoR I and EcoRV sites were retained between the adenoviral sequences at the deleted E1a location. The Ad7 E1b and pIX sequences (2712-3897 bp), an EcoR V-Bgl II fragment from plasmid pAd7DE1a, were further deleted to generate pAd7LDE1. pAd7 M was generated by insertion of the middle Sal I-Sal I fragment (6358-26 000 bp) from Ad7 at the Sal I site of the pUC19 vector. pAd7RDE3 (80-88 mu) was provided by Wyeth-Lederle Vaccines.
Preparation and purification of cosmid DNA
Cosmid DNA was prepared using the alkaline lysis method and further purified on Qiagen columns. For cloning, the SuperCos 1 cosmid vector (Stratagene) was first digested with either EcoR I or Not I, filled-in and then digested with Xba I and dephosphorylated. The sotreated, extracted large (6.8 kb) and small (1.1 kb) cos arms can accommodate foreign DNA inserts ranging in size from 30 to 42 kb. Ligated DNAs were packaged into phage l using Gigapack III XL packaging extract (Stratagene) according to the manufacturer's protocol. The Escherichia coli XL1-Blue MR host strain (Stratagene) was then infected with the packaged bacteriophage. Recombinant cosmid DNAs in individual colonies formed on LB plates containing ampicillin were miniprepared by the alkaline lysis method and analyzed by restriction endonuclease digestion. Correct colonies were further cultured in Super Broth (ABI). Recombinant DNAs were purified on EndoFree Plasmid Maxi Kit columns without a filter (QIAGEN) for eucaryotic transfection.
Construction of Ad7 and Ad7 recombinant cosmids cAd7 was generated by ligation and packaging of the two EcoR I-treated cos arms with isolated wild-type Ad7 genomic DNA. cAd7DE3HIV MN env/rev-E was generated by ligation and packaging of the two EcoR I-treated cos arms with isolated virus DNA from Ad7DE3HIV MN env/ rev (Wyeth-Lederle Vaccines) in which the E3 gene (80-88 mu) was replaced with a concatemer of the Ad7 tripartite leader (TPL) and the HIV env and rev genes (TPL-env-TPL-rev). cAd7DE3HIV MN env/rev-N was similarly generated by ligation and packaging of the two Not I-treated cos arms with Ad7DE3HIV MN env/rev genomic DNA. To construct cAd7DE1DE3HIV MN env/rev, the Acc 65I-Acc 65I digested, filled-in fragment from pAd7LDE1 (containing the left Sal I fragment of Ad7 lacking the E1 and pIX genes (467-3898 bp)) was inserted in the SuperCos 1 cosmid vector deleted EcoR I-EcoR I fragment (2-66), yielding cAd7LDE1. cAd7DE1DE3HIV MN env/rev was then generated through a three-way DNA ligation: a left Xba I-Sal I fragment from cAd7LDE1 (containing the left Sal I fragment of Ad7 lacking the E1 gene and the large cos arm); a middle Sal I-Pac I fragment from pAd7M; and a right Pac I-EcoR I fragment from cAd7DE3HIV MN env/rev-E (containing Ad7 DNA from the Pac I site located at ca 54 mu to the right end of virus genome, the HIV gene inserts in the deleted E3 region and the small cos arm).
Generation of recombinant adenovirus
The recombinant cosmid was digested to release the Ad genome, which was precipitated with ethanol. The pellet was resuspended in sterile TE (10 mM Tris-HCl, pH 7.5 containing 1 mM EDTA). Transfection into 293-ORF6 cells was performed using the Ca 2 PO 4 method (Invitrogen) according to the manufacturer's protocol. Briefly, 2 Â 10 6 cells were seeded in a T75 tissue culture flask the day before transfection and fed with fresh, serum-free medium 3 h before transfection. Nearly confluent cell monolayers were transfected with 10 mg of the released Ad DNA. Approximately 4-6 h later, the medium was supplemented with 10% fetal calf serum and 100 mM ZnCl 2 to induce E4-ORF6 expression. 51 Twenty-four hours after transfection the medium was replaced with fresh, complete DMEM containing ZnCl 2 . Large, clear plaques appeared 6-10 days later. Virus was harvested and further amplified in 293-ORF6 cells.
Crude virus was released from the infected cells by three cycles of freeze-thawing and the virus suspension was further purified through two CsCl gradients. Viral DNA was isolated from either the crude virus product or from CsCl-purified adenovirus. 64 Briefly, virus suspensions were first treated with capsid lysis buffer (20 mM Tris-HCl and 10 mM EDTA) and RNAase at 371C for 1 h, and then digested with proteinase K (0.2 mg/ml) at 561C for 3 h. Ad DNA was further extracted with phenol and precipitated with ethanol. The isolated viral DNA was characterized by restriction enzyme and PCR analysis.
Identification of recombinant adenoviruses by restriction enzyme analysis and PCR amplification
To verify the Ad recombinants, viral DNAs (25 ml) were digested with 20 U of Sal I (Roche, Indianapolis, IN, USA) in a total volume of 30 ml at 371C for 3 h, subjected to electrophoresis on 0.8% agarose gels, and stained with ethidium bromide (1 mg/ml). Polymerase chain reactions (PCR) were performed on isolated viral DNAs to verify the presence or absence of the Ad7 E1 and pIX genes in individual recombinants. PCRs were performed in 50 ml mixtures containing 0.5 mM each of the primer pair, 200 mM of each deoxynucleoside triphosphate (dNTP), 5 ml of 10-fold concentrated buffer, and 2.5 U of Ampli Taq Gold TM DNA polymerase (PE Applied Biosystems). DNA templates consisted of 500-800 ng of viral DNAs and were amplified using an Ad7 E1 flanking forward primer (260-GGCGGATG-CAAGTGAAAATTCTCC-284) and a reverse primer (4228-TAAACACCTACACTAAGGGCCTCC-4204). PCR was performed on a GeneAmp PCR System 9700 Generation of a replication-defective Ad7 vector X Nan et al thermocycler (PE Applied Biosystems), using an initial 15 min 941C denaturation; a 35 cycle program consisting of a 45-s denaturation at 941C, a 1-min annealing at 631C, and a 4-min extension at 721C; and a final 12-min extension at 721C. Amplicons (50 ml) were then separated on 1.0% agarose gels and stained with ethidium bromide. The lysates of cells infected with Ad recombinants were clarified by centrifugation at 13,200 rpm for 20 min. For evaluation of Rev expression, supernatants were subjected to SDS-PAGE and electroblotted at 20 V overnight at 41C onto a polyvinylidene difluoride (PVDF) membrane (PIERCE). The membrane was blocked with equal volumes of SuperBlock TM blocking buffer in PBS (PIERCE) and PBS containing 0.05% Triton X-100. Rev expression was detected by probing with a 1:10 000 dilution of sheep anti-HIV Rev serum (US Biological) followed by a 1:100 000 dilution of rabbit anti-goat peroxidase-linked secondary antibody (PIERCE). Rev protein was visualized using enhanced chemiluminescence detection (ECL, PIERCE).
For evaluation of envelope expression, clarified cell lysates were first immune precipitated with 1 mg of monoclonal antibody 2F5, specific for the HIV transmembrane protein gp41 (NIH AIDS Research & Reference Reagent Program), as specified in the technical manual (Roche). The precipitated proteins were subjected to SDS-PAGE and electroblotted as above. Envelope expression was evaluated by probing with the 2F5 antibody at a concentration of 10 ng/ml followed by a 1:10 000 dilution of goat anti-human peroxidaselinked secondary antibody (Amersham). The proteins were visualized using ECL (Amersham).
HIV envelope expression was further assessed by a syncytia induction assay. 293-ORF6 cell monolayers (70% confluent) were infected with the Ad recombinant viruses. Four hours later the monolayers were overlaid with CEMx174 cells, 65 a human CD4 + T-lymphocyte cell line, at a ratio of 10:1 CEMx174 to 293-ORF6 cells. The cocultures were evaluated daily for the presence of multinucleated giant cells.
